Loading
DROSHA (Ribonuclease 3) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Brain and spinal cord tumours, Pancreatic ductal adenocarcinoma and 5 more.
Ribonuclease III double-stranded (ds) RNA-specific endoribonuclease that is involved in the initial step of microRNA (miRNA) biogenesis. Component of the microprocessor complex that is required to process primary miRNA transcripts (pri-miRNAs) to release precursor miRNA (pre-miRNA) in the nucleus. Within the microprocessor complex, DROSHA cleaves the 3' and 5' strands of a stem-loop in pri-miRNAs (processing centre 11 bp from the dsRNA-ssRNA junction) to release hairpin-shaped pre-miRNAs that are subsequently cut by the cytoplasmic DICER to generate mature miRNAs.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.78 (direct and indirect evidence; datatypes literature 0.95, genetic association 0.83, somatic mutation 0.92). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Lung Squamous Cell Carcinoma, Pancreatic Adenocarcinoma, Wilms' Tumour.
In plain words · DROSHA (Ribonuclease 3) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Brain and spinal cord tumours, Pancreatic ductal adenocarcinoma and 5 more.
DROSHA (Ribonuclease 3) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Brain and spinal cord tumours, Pancreatic ductal adenocarcinoma and 5 more.
Ribonuclease III double-stranded (ds) RNA-specific endoribonuclease that is involved in the initial step of microRNA (miRNA) biogenesis.
No product in this corpus aims at DROSHA yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA DROSHA: RNA low tissue specificity; no normal tissue stained high. Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Brain and spinal cord tumours (all types), Pancreatic ductal adenocarcinoma, Ovarian cancer, Lung cancer (all types), Skin cancer (all types), Gastric & gastro-oesophageal junction cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q9NRR4; CIViC gene DROSHA; IntOGen DROSHA; Human Protein Atlas DROSHA tissue; Open Targets ENSG00000113360 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Wei Y.J. et al, 1998. Source.
Sources: HGNC HGNC:17904 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NRR4 (protein name, function text, keywords and locations (REST API)); CIViC gene DROSHA (1 evidence items, 0 assertions, 1 variants; diseases: Renal Wilms' Tumour (GraphQL API, CC0)); Open Targets ENSG00000113360 (association with cancer (MONDO_0004992) 0.78; per-cancer scores at or above 0.5: gastric cancer 0.51, ovarian cancer 0.56, skin cancer 0.55, brain cancer 0.57, breast cancer 0.63, lung cancer 0.56 (GraphQL API, CC0)); IntOGen DROSHA (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Ribonuclease III double-stranded (ds) RNA-specific endoribonuclease that is involved in the initial step of microRNA (miRNA) biogenesis. Component of the microprocessor complex that is required to process primary miRNA transcripts (pri-miRNAs) to release precursor miRNA (pre-miRNA) in the nucleus. Within the microprocessor complex, DROSHA cleaves the 3' and 5' strands of a stem-loop in pri-miRNAs (processing centre 11 bp from the dsRNA-ssRNA junction) to release hairpin-shaped pre-miRNAs that are subsequently cut by the cytoplasmic DICER to generate mature miRNAs. Involved also in pre-rRNA processing. Cleaves double-strand RNA and does not cleave single-strand RNA. Involved in the formation of GW bodies. Location: Nucleus; Nucleus, nucleolus; Cytoplasm (UniProt). Locus 5p13.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
HPA DROSHA tissue · HPA DROSHA pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"DROSHA" OR ABSTRACT:"DROSHA" OR TITLE:"drosha ribonuclease III" OR ABSTRACT:"drosha ribonuclease III" OR TITLE:"Ribonuclease 3" OR ABSTRACT:"Ribonuclease 3" OR TITLE:"RNASE3L" OR ABSTRACT:"RNASE3L" OR TITLE:"Etohi2" OR ABSTRACT:"Etohi2" OR TITLE:"HSA242976" OR ABSTRACT:"HSA242976") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DROSHA, not a curated reading list.
Shares Brain and spinal cord tumours (all types), Skin cancer (all types), Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
Shares Brain and spinal cord tumours (all types), Skin cancer (all types), CIViC, IntOGen.
Shares Brain and spinal cord tumours (all types), CIViC, Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
Shares Brain and spinal cord tumours (all types), IntOGen, Open Targets Platform.
Shares Brain and spinal cord tumours (all types), Ovarian cancer, Non-small-cell lung cancer.
Shares Brain and spinal cord tumours (all types), Non-small-cell lung cancer.
Shares Brain and spinal cord tumours (all types), Lung cancer (all types), Non-small-cell lung cancer.
Shares Brain and spinal cord tumours (all types), Non-small-cell lung cancer.